tirzepatide for cardiovascular disease effects of In patients with type 2

Retatrutide: not yet available through standard channels Retatrutide is not FDA-approved

Originally developed for diabetes and weight loss, these medications are now being recognized for their profound benefits in treating core drivers of PCOS , including insulin resistance , excess androgens , and chronic inflammation

This is a placebo-controlled study with a duration of 72 weeks (83)

Torres, K

Keywords: Basal insulin, GLP-1 receptor agonists, Glycaemic control, Network meta-analysis, Tirzepatide, Type 2 diabetes mellitus Key Summary Points Introduction Type 2 diabetes mellitus (T2DM) is a progressive metabolic disease characterised by chronic hyperglycaemia [1]